Aarti Pharmalabs Limited (NSE:AARTIPHARM)
India · Delayed Price · Currency is INR | Market Cap | 73.89B -3.7% |
| Revenue (ttm) | 19.69B +1.2% |
| Net Income | 2.05B -23.1% |
| EPS | 22.56 -23.2% |
| Shares Out | 90.68M |
| PE Ratio | 36.12 |
| Forward PE | 46.56 |
| Dividend | 3.50 (0.43%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 568,907 |
| Open | 832.00 |
| Previous Close | 828.80 |
| Day's Range | 782.00 - 832.00 |
| 52-Week Range | 585.00 - 1,002.40 |
| Beta | 0.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Aarti Pharmalabs
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, ophthalmologic, antidepressant medications. It also ... [Read more]
Financial Performance
In fiscal year 2026, Aarti Pharmalabs's revenue was 18.19 billion, a decrease of -13.98% compared to the previous year's 21.15 billion. Earnings were 1.75 billion, a decrease of -35.86%.
Financial StatementsNews
Aarti Pharmalabs Transcript: Q1 26/27
Standalone Q1 FY27 revenue rose 42% YoY to ₹535 crore and PAT increased 49% to ₹71 crore. FY27 guidance includes 22%–25% standalone EBITDA margin and 40%–50% CDMO/CMO growth, weighted to H2.
Aarti Pharmalabs Slides: Q1 2027
Aarti Pharmalabs has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 10, 2026.
Aarti Pharmalabs Quarterly report: Q1 2027
Aarti Pharmalabs has published its Q1 2027 quarterly earnings report on August 10, 2026.
Aarti Pharmalabs Transcript: Q4 25/26
FY26 revenue rose to INR 1,798 crore, while EBITDA and PAT declined amid forex and cost pressures. Record CDMO and Xanthine sales, capacity ramp-ups and 15%-18% long-term growth guidance frame the outlook.
Aarti Pharmalabs Slides: Q4 2026
Aarti Pharmalabs has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 26, 2026.
Aarti Pharmalabs Annual report: Q4 2026
Aarti Pharmalabs has published its Q4 2026 annual report on May 26, 2026.
Aarti Pharmalabs Quarterly report: Q4 2026
Aarti Pharmalabs has published its Q4 2026 quarterly earnings report on May 26, 2026.
Aarti Pharmalabs Transcript: Q3 25/26
Q3 revenue and PAT declined YoY, while EBITDA was nearly flat. Atali start-up delays and softer APIs temper FY26 growth, with CDMO and xanthine capacity expected to support future expansion.
Aarti Pharmalabs Slides: Q3 2026
Aarti Pharmalabs has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 10, 2026.
Aarti Pharmalabs Quarterly report: Q3 2026
Aarti Pharmalabs has published its Q3 2026 quarterly earnings report on February 10, 2026.
Aarti Pharmalabs Transcript: Q2 25/26
Q2 consolidated revenue and EBITDA declined YoY, with API mix pressure and forex loss weighing on earnings. FY26 standalone EBITDA growth guidance is 8%-12%, while CDMO/CMO growth is expected to exceed 30%-40%.
Aarti Pharmalabs Slides: Q2 2026
Aarti Pharmalabs has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 11, 2025.
Aarti Pharmalabs Quarterly report: Q2 2026
Aarti Pharmalabs has published its Q2 2026 quarterly earnings report on November 11, 2025.